We have reported that transplantation of adrenal medullary chromaffin cells that release endogenous opioid peptides into pain modulatory regions in the CNS produce significant antinociceptive effects in patients with terminal cancer pain. However, the usefulness of this procedure is minimal because the availability of human adrenal tissue is very limited. Alternative xenogeneic materials, such as porcine and bovine adrenal chromaffin cells present problems of immune rejection and possible pathogenic contamination. In an attempt to develop opioid peptide-producing cells of autologous origin, we have transfected human mesenchymal stem cells (hMeSCs) with a mammalian expression vector containing a fusion gene of green fluorescent protein (GFP) and human preproenkephalin (hPPE), a precursor protein for enkephalin opioid peptides. Enkephalins are major neurotransmitters that play an important role in analgesia by activating peripheral opioid receptors. Following the establishment of stable transfection of hMeSCs, the expressions of hPPE and GFP were confirmed and the production of methionine enkephalin (Met-enkephalin) was significantly increased compared to control naive hMeSCs (p < 0.05). Our in vitro data demonstrated that genetically engineered hMeSCs with transfected hPPE gene can constitutively produce opioid peptide Met-enkephalin at an augmented high level. hMeSCs are relatively easy to isolate from a patient's bone marrow aspirates and expand in culture by repeated passages. Autologous hMeSCs would not require immunosuppression when transplanted back into the same patient. Through targeted gene manipulation such as hPPE gene transfection, this may offer a virtually unlimited safe cell supply for the treatment of opioid-sensitive pain in humans.
INTRODUCTION
cal need for suitable sources of chromaffin cells is obvious. Bovine or porcine adrenal medullary tissue may provide alternative cell sources; however, these cells Previous studies have shown that transplantation of xenogeneic adrenal medullary tissue or isolated chro-elicit host immunological response to the transplants (2, 7) . Immunosuppression is necessary for the prolonged maffin cell suspensions into the spinal subarachnoid space produces antinociception in rats and in nonhuman survival of the transplants, and immunosuppression may result in serious problems, including an increased sus-primates (7, 17, 18, 20) . Initial clinical trials using allogeneic adrenal chromaffin tissue provided pain relief in ceptibility to tumor growth and infections. Although chromaffin cells are not very immunogenic and purified patients with terminal cancer (4, 11, 26) . Adrenal medulary chromaffin cells synthesize and release several com-xenogeneic chromaffin cells can minimize immunorejection, even a small number of passenger cells (i.e., fi-pounds, including enkephalins and catecholamines (5, 23) . These agents reduce pain sensitivity when injected di-broblast and endothelial cells) in the transplant preparation are highly immunogenic (2,10). In our experience rectly into the spinal cord subarachnoid space (7, 16, 17) . However, availability of human adrenal tissue to serve with purified chromaffin cell transplants, a clear decrease in transplant function over time occurs (7) . For as allografts for transplantation is very limited. Because effective therapy of a single patient requires large amounts example, with xenogeneic chromaffin cell transplants, the attenuation of pain may last only 3 weeks without of isolated chromaffin cells for transplantation, the clini-226 SUGAYA ET AL. immunosuppression (7) , while analgesia can last longer cells were incubated at 37°C in a 5% CO 2 humidified incubation chamber (Fisher, Pittsburgh, PA). The cells (at least 5 weeks) with immunosuppression (20) . The reasons for the gradual decline in analgesic effect are were fed by replacing half the culture medium twice per week. not yet clear; it may involve several factors in which immunorejection cannot be excluded, because the ad-Transfection of Human Preproenkephalin (hPPE) ministration of immunosuppression itself enhances longer term graft survival and extends the analgesic effect
The hPPE cDNA (pGEMhPPE) was a gift from Dr. S. P. Wilson (University of South Carolina, School of (7, 9) . In addition, there has been a concern regarding pathogen contamination of bovine spongiform encepha-Medicine, Department of Pharmacology, Physiology and Neuroscience). The hPPE cDNA was dissected out from lopathy for bovine chromaffin cell transplantation. Therefore, the ideal cell source would be autologous cells de-pGEMhPPE by digestion with EcoRI and HindIII. The hPPE cDNA was purified on a gel (960 bp) and then rived from the patient's own tissue.
With the advance of in vitro gene technology, there ligated into EcoRI and HindIII site of pcDNA3.1(−)/Zeo (Invitrogen), human cytomegalovirus (CMV) promoter-is a potential for genetically engineering the cells derived from a patient's own peripheral tissue for targeted based constitutive expression vectors [pcDNA3.1(−)/zeo/ hPPE]. To produce enhanced green fluorescent protein clinical use (12, 13, 21, 24, 25) . Autologous human mesenchymal stem cells (hMeSCs) are relatively easy to iso-(EGFP) fusion hPPE, pcDNA3.1(−)/zeo/hPPE was digested by XhoI and HindIII and the resulting fragment late from bone marrow aspirates and then expand in culture by repeatable passages. These cells are favorable (993 bp) was cloned into the pEGFP (BD Bioscience, Palo Alto, CA) XhoI and HindIII site (pEGFP/hPPE). candidates for further genetic manipulation because they are able to proliferate and potentially differentiate into All the clones were confirmed by DNA sequencing. Endotoxin-free plasmids are prepared by NucleoBond Plas-the cell lineage of various types including neural phenotypes and survive for prolonged period when trans-mid EF Kit (BD Bioscience) from bacterial cultures. Transfection of the gene to the hMeSCs was performed planted into the CNS (1, 14, 19, 27) . Preproenkephalin (PPE) is the precursor protein for enkephalins and en-by using NeuroPORTOR (Gene Therapy Systems, Inc., San Diego, CA) by following the protocol provided by kephalin opioid peptides such as Met-and Leu-enkephalin, which are important neurotransmitters for inhibition the manufacturer. After the transfection, GFP expression was checked with a Leica fluorescent microscope. of nociception (3, 5, 6, 15, 25) . Following transfection, the expression of human PPE (hPPE) and green fluorescent Gene Expression Analysis by RT-PCR protein (GFP) genes and the production of Met-enkephalin in MeSCs were examined by RT-PCR and an immu-Four days after transfection, hPPE and GFP gene expressions were analyzed by RT-PCR. RNAs were iso-noblot assay, respectively. Our results demonstrated that these genetically engineered hMeSCs have an enhanced lated from the cells using TRIzol reagent (Invitrogen) and treated with RNAase-free DNAase (Promega, Madi-hPPE gene expression and increased release of Metenkephalin in culture conditions. As a first step, we have son, WI). RT-PCR was performed using SuperScript One-Step RT-PCR with Platinum Taq (Invitrogen) using successfully manipulated hMeSCs genetically to produce more opioid peptide Met-enkephalin by targeted gene-specific primer sets: hPPE (5′-ACATCAACTTCC TGGCTTGCGT-3′ and 5′-GCTCACTTCTTCCTCATT gene transfection. hMeSCs are dividing cells and proliferate in culture with repeated passages. These autolo-ATCA-3′), GFP (5′-CAAGGACGACGGCAACTACA AGACC-3′ and 5′-GCGGACTGGGTGCTCAGGTAGT gous Met-enkephalin-producing hMeSCs may offer a virtually unlimited safe cell supply and have promise of GGT-3′). DNA samples resulting from RT-PCR were analyzed on 2% E-Gel (Invitrogen). serving as a useful alternative to adrenal chromaffin cells for the clinical treatment of opioid-sensitive pain.
Immunoblot Assay for Met-Enkephalin MATERIALS AND METHODS in the Culture Media Cell Cultures
The serum-supplemented growth medium for hMeSCs was replaced by serum-free medium (DMEM with anti-hMeSCs were purchased from Cambrex (Walkersville, MD), which were negative for CD11b, CD33, biotic-antimycotic) 1 day before Met-enkephalin assay. Twenty-four hours later, medium was collected and pu-CD34, and CD133 antigens. hMeSCs were cultured in 75-cm 2 
RESULTS
The hMeSCs transfected with GFP/hPPE fused gene were grown at 37°C for 24 h before in vitro analysis. These cells retained their ability to proliferate at a speed similar to that of the hMeSCs without gene transfection. Under the culture condition as mentioned above, these cells can double themselves by 7 days. was analyzed by RT-PCR. As expected, the molecular size of the RT-PCR product for hPPE and GFP gene fragments was 425 and 318 bp, respectively. Naive when compared with naive hMeSCs (p < 0.05) (Fig. hMeSCs expressed hPPE; however, transfection of GFP/ 2Fig. 2). Following transfection of GFP/hPPE/, GFP ex-hPPE into hMeSCs greatly enhanced hPPE gene exprespression of hMeSCs was detected as green fluorescencesion in these cells (Fig. 1) .
labeled cells under fluorescence microscope (Fig. 3 ).
Production and Release of Met-Enkephalin DISCUSSION
Our present study demonstrates that hMeSCs trans-The serum-supplemented growth medium for hMeSCs was replaced by serum-free medium (DMEM with anti-fected with a vector containing a fused hPPE and GFP gene were able to express both hPPE and GFP genes biotic-antimycotic) 1 day before immunoblot assay for Met-enkephalin. Twenty-four hours later, medium was and constitutively produce a high level of Met-enkephalin opioid peptide in cell culture. As assessed by RT-collected and purified for immunoblot assay. Naive hMeSCs were able to produce and release of Met-PCR and an immunoblot assay, our results reveal that naive hMeSCs have an inherent but weak PPE gene ex-enkephalin opioid peptide into the culture medium at a basal level of 1.731 ± 0.124 pg/cell/24 h. Then we as-pression and are spontaneously able to release a basal level of Met-enkephalin at a rate of 1.731 ± 0.124 pg/ sessed whether the transgenic GFP/hPPE were able to drive the production and secretion of Met-enkephalin cell/24 h in the cultured condition. Four days after hPPE gene transfection, hMeSCs obtained an enhanced hPPE opioid peptide in the transfected hMeSC population. We found that the gene transfected hMeSCs had a signifi-expression and the production of Met-enkephalin significantly increased at a rate of 2.42 ± 0.46 pg/cell/24 h cantly augmented production and release of Met-enkephalin opioid peptide at a rate of 2.42 ± 0.46 pg/cell/24 h, (p < 0.05) (Fig. 3) . Therefore, genetic enhancement of 228 SUGAYA ET AL.
peptides released by the transplanted cells because it can be blocked by intrathecal administration of the opioid antagonist naloxone. These results suggest that the genetically engineered cells expressing hPPE and producing Met-enkephalin have promise to serve as a useful alternative to adrenal chromaffin cells in pain treatment. As reported previously, transplantation of xenogenic adrenal medullary tissue or isolated medullary chromaffin cell suspensions into the pain modulatory regions in the CNS can produce robust antinociceptive effect in animal pain models (16, 18, 20) . Preliminary clinical trials using allogenic adrenal medullary tissue produced a long-term analgesic effect in patients with refractory cancer pain without development of tolerance (4, 11, 26) . Beside the limited availability of allogeneic adrenal tissue and the lack of tissue for individual transplantation, there is a concern regarding immunorejection and pathogen contamination for adrenal tissues of xenogeneic sources (2,7). It would be ideal to develop a new source of autologous cells derived from the patient's own peripheral tissue because the cells of an autologous origin would not require immune suppression when transplanted back to the same patient. Our present study demonstrated that hMeSCs could be a favorable autologous cell candidate for generating chromaffin cell-like cells through further gene manipulation because these cells Wilson and colleagues and others (3, 6, 15, 25) have introduced the hPPE gene to sensory neurons by a herpes-mediated gene delivery system that successfully hMeSCs by targeted hPPE gene transfection significantly increased their ability to produce more Met-modulates certain types of nociceptive reactions in experimental pain models. In an effort to develop a new enkephalin. In accordance with naive MeSCs, the genetically enhanced Met-enkephalin-producing hMeSCs source of chromaffin-like cells from an autologous source of cells, we genetically transfected hMeSCs with a were stable and retained their ability to proliferate in vitro, suggesting that these cells are both viable and mammalian expression vector containing a fused gene of hPPE and enhanced GFP and successfully generated functional. Thus, we have successfully generated expandable hMeSCs into Met-enkephalin opioid peptide-hMeSCs opioid peptide Met-enkephalin-producing cells without viral delivery. Because autologous hMeSCs are producing cells, which can release Met-enkephlin at the similar levels to normally found in the primary chromaf-easily isolated from patients' own peripheral tissues and are expandable in cell culture for further gene manipula-fin cells.
We have previously briefly described a similar ap-tion, our approach may provide a favorable alternative to adrenal chromaffin cell transplantation in the treat-proach of hPPE gene transfection into human neuroncommitted teratocarcinoma (NT-2) cells (8) . These gene ment of opioid-sensitive chronic pain, a treatment that will not cause host immune rejection and thereby im-transfected NT-2 cells expressed hPPE gene and produce Met-enkephalin. A subpopulation of them can be proving analgesic efficacy. By avoiding the use of viral vectors as a vehicle to deliver a target gene into pain terminally differentiated into neurons by retinoic acid treatment. When transplanted intrathecally into a rat modulatory regions, the strategies of in vitro gene manipulation of autologous cells may hold the promise of pain model, the differentiated neuronal cells derived from NT-2 cells transfected with hPPE gene demon-providing safer and more efficacious approaches for targeted clinical application. strated antinociception at an efficacy similar to that observed with chromaffin cell transplantation (8) . The re-
The hMeSCs are able to proliferate and have the potential to differentiate into the cell lineage of various duced pain sensitivity is obviously mediated by opioid types, including the ability of acquiring neural pheno-mental data about the therapeutic potential of autologous hMeSCs transfected by hPPE gene in pain treatment. types both in vitro and in vivo and surviving for prolonged periods when transplanted into the brain (1, 14, We demonstrated that naive hMeSCs have a low level of endogenous hPPE gene expression and low level of 19,27), suggesting the feasibility of hMeSCs for CNS transplantation. After gene transfection, these cells re-Met-enkephalin production and that gene-enhanced hMeSCs by hPPE transfection are able to constitutively tained the capacity for proliferation and differentiation. These properties of hMeSCs make them valuable when produce Met-enkephalin and spontaneously release Metenkephalin at a high level in the cell culture. The hPPE they are used as vehicles for the release of neuroactive substances into the host CNS environment and function expression was confirmed by RT-PCR, and the level of Met-enkephalin production was examined by an immu-as a biological pump, providing an endogenous source of renewable neuroactive substances. noblot assay. The data obtained from our studies suggest that hMeSCs transfected with hPPE gene without viral Unlike chromaffin cells, which are postmitotic, hMeSCs are self-renewal stem cells. Because these ge-delivery may serve as a suitable alternative to adrenal chromaffin cells for transplantation to control chronic netically engineered hMeSCs can multiply in culture over repeated passages, this source of cells may offer a pain. sufficient cell supply for the need of transplantation. Our hMeSCs. Our results provide the first in vitro experi-
